BRPI0608840B8 - composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação - Google Patents

composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação

Info

Publication number
BRPI0608840B8
BRPI0608840B8 BRPI0608840A BRPI0608840A BRPI0608840B8 BR PI0608840 B8 BRPI0608840 B8 BR PI0608840B8 BR PI0608840 A BRPI0608840 A BR PI0608840A BR PI0608840 A BRPI0608840 A BR PI0608840A BR PI0608840 B8 BRPI0608840 B8 BR PI0608840B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
omega
substituted diphenyl
preparation process
diphenyl urea
Prior art date
Application number
BRPI0608840A
Other languages
English (en)
Inventor
Wollenschläger Axel
Schückler Fritz
Original Assignee
Batyer Healthcare Ag
Bayer Healthcare Llc
Bayer Ip Gmbh
Bayer Pharma AG
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36507604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0608840(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Batyer Healthcare Ag, Bayer Healthcare Llc, Bayer Ip Gmbh, Bayer Pharma AG, Bayer Schering Pharma Ag filed Critical Batyer Healthcare Ag
Publication of BRPI0608840A2 publication Critical patent/BRPI0608840A2/pt
Publication of BRPI0608840B1 publication Critical patent/BRPI0608840B1/pt
Publication of BRPI0608840B8 publication Critical patent/BRPI0608840B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica compreendendo uma difenil uréia substituída por ômega - carboxiarila para o tratamento de câncer. a presente invenção refere-se a uma composição farmacêutica compreendendo o composto de fórmula (1) em uma alta concentração e pelo menos um excipiente farmaceuticamente aceitável, ao uso da composição para o tratamento de doenças hiperproliferativas tais como câncer, tanto como um agente único ou em combinação com outras terapias anticâncer, e ao processo de preparação da referida composição.
BRPI0608840A 2005-03-07 2006-02-22 composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação BRPI0608840B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65882705P 2005-03-07 2005-03-07
PCT/EP2006/001574 WO2006094626A1 (en) 2005-03-07 2006-02-22 Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer

Publications (3)

Publication Number Publication Date
BRPI0608840A2 BRPI0608840A2 (pt) 2010-02-02
BRPI0608840B1 BRPI0608840B1 (pt) 2020-04-14
BRPI0608840B8 true BRPI0608840B8 (pt) 2021-05-25

Family

ID=36507604

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608840A BRPI0608840B8 (pt) 2005-03-07 2006-02-22 composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação

Country Status (38)

Country Link
US (2) US9737488B2 (pt)
EP (1) EP1868579B1 (pt)
JP (1) JP5304241B2 (pt)
KR (1) KR101335932B1 (pt)
CN (2) CN104688697A (pt)
AR (1) AR054234A1 (pt)
AT (1) ATE482693T1 (pt)
AU (1) AU2006222365B2 (pt)
BR (1) BRPI0608840B8 (pt)
CA (1) CA2601955C (pt)
CR (1) CR9348A (pt)
CU (1) CU23821A3 (pt)
CY (1) CY1111065T1 (pt)
DE (1) DE602006017188D1 (pt)
DK (1) DK1868579T3 (pt)
DO (1) DOP2006000057A (pt)
ES (1) ES2351612T3 (pt)
GT (1) GT200600096A (pt)
HK (1) HK1209620A1 (pt)
HN (1) HN2006009702A (pt)
HR (1) HRP20100674T1 (pt)
IL (1) IL185517A (pt)
MA (1) MA29378B1 (pt)
MX (1) MX2007010856A (pt)
MY (1) MY162319A (pt)
NO (1) NO343834B1 (pt)
NZ (1) NZ561178A (pt)
PE (1) PE20061345A1 (pt)
PL (1) PL1868579T3 (pt)
PT (1) PT1868579E (pt)
SG (1) SG160364A1 (pt)
SI (1) SI1868579T1 (pt)
TN (1) TNSN07341A1 (pt)
TW (1) TWI324928B (pt)
UA (1) UA93673C2 (pt)
UY (1) UY29410A1 (pt)
WO (1) WO2006094626A1 (pt)
ZA (1) ZA200707638B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
KR101381454B1 (ko) 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
SG160364A1 (en) 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CA2627875A1 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP5885012B2 (ja) 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010142678A2 (en) * 2009-06-12 2010-12-16 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
AU2011210326B2 (en) * 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
MA34553B1 (fr) 2010-10-01 2013-09-02 Bayer Ip Gmbh Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
IN2014KN01490A (pt) 2012-01-23 2015-10-23 Sandoz Ag
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10597820B2 (en) * 2015-05-14 2020-03-24 DuPont Nutrition USA, Inc. Method of making bleached microcrystalline cellulose
US11324829B2 (en) * 2016-03-14 2022-05-10 Santen Pharmaceutical Co., Ltd. Antiseptic agent comprising meglumine or salt thereof
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
CN106344530B (zh) * 2016-09-30 2019-03-19 京津冀联创药物研究（北京）有限公司 一种索拉非尼组合物及其制备方法
RU2019138742A (ru) 2017-05-26 2021-06-28 Бруин Байосаенсис, Инк. Средства для химиоэмболизации
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en) 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Solid dosage form containing sorafenib tosylate
CN113677346A (zh) 2018-11-01 2021-11-19 希洛斯医药品股份有限公司 周期蛋白依赖性激酶7(cdk7)的抑制剂
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125359A (en) * 1964-03-17 Push-pull breakaway coupling
NL282262A (pt) * 1961-11-08
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP0841910A4 (en) 1995-07-25 2006-09-13 Smithkline Beecham Corp INHIBITION OF A TRANSACYLASE INDEPENDENT OF COENZYME A (CoA) AND APOPTOSIS
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
WO1998052558A1 (en) 1997-05-23 1998-11-26 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
ATE399007T1 (de) 1997-05-23 2008-07-15 Bayer Pharmaceuticals Corp Raf kinase hemmer
SK286213B6 (sk) 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
BR9814375A (pt) 1997-12-22 2002-05-21 Bayer Ag Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ID26328A (id) 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20030087849A1 (en) 2001-07-03 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of HKR1 expression
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IL144461A0 (en) * 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
JP2004506680A (ja) * 2000-08-18 2004-03-04 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP4982685B2 (ja) * 2001-12-03 2012-07-25 バイエル、ファーマシューテイカルズ、コーポレイション ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
DE602004030222D1 (de) 2003-02-28 2011-01-05 Bayer Healthcare Llc 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
EP1603879A2 (en) 2003-02-28 2005-12-14 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
EP1608639A2 (en) 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US6896863B2 (en) * 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
BRPI0414698A (pt) * 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
US7552093B2 (en) * 2003-12-04 2009-06-23 Black Duck Software, Inc. Resolving license dependencies for aggregations of legally-protectable content
US20070134670A1 (en) 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CN101010315A (zh) * 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
JP2008503560A (ja) 2004-06-22 2008-02-07 ファイザー・プロダクツ・インク ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006026501A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
KR101381454B1 (ko) 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
AU2005289099B2 (en) 2004-09-29 2012-07-19 Bayer Healthcare Llc Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
SG160364A1 (en) 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
KR20080018908A (ko) 2005-05-27 2008-02-28 바이엘 헬스케어 아게 암 치료용 디아릴 우레아 화합물 및 ｐｉ３, ａｋｔ 키나제또는 ｍｔｏｒ 억제제 (라파마이신)를 포함하는 병용요법
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
EP1937837A2 (en) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
BRPI0617488A2 (pt) * 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
CA2627875A1 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2628091A1 (en) 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CN101351709A (zh) * 2005-11-02 2009-01-21 拜尔健康护理有限责任公司 癌症的预测和预后以及监控癌症治疗的方法
WO2007054215A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating pulmonary hypertension
KR20080073745A (ko) * 2005-11-14 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 요법을 모니터하는방법
WO2007059155A1 (en) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
WO2007059154A2 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
JP2009518298A (ja) 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
DK2111401T3 (da) 2006-12-20 2011-05-30 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer
JP5885012B2 (ja) 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Also Published As

Publication number Publication date
MX2007010856A (es) 2007-11-12
KR20070111513A (ko) 2007-11-21
CU20070203A7 (es) 2010-01-22
IL185517A (en) 2016-05-31
IL185517A0 (en) 2008-01-06
CY1111065T1 (el) 2015-06-11
JP5304241B2 (ja) 2013-10-02
PL1868579T3 (pl) 2011-03-31
RU2420283C2 (ru) 2011-06-10
MA29378B1 (fr) 2008-04-01
ZA200707638B (en) 2009-08-26
EP1868579A1 (en) 2007-12-26
EP1868579B1 (en) 2010-09-29
NO20075042L (no) 2007-10-05
MY162319A (en) 2017-05-31
CN104688697A (zh) 2015-06-10
ATE482693T1 (de) 2010-10-15
RU2007136896A (ru) 2009-04-20
NZ561178A (en) 2010-11-26
UA93673C2 (ru) 2011-03-10
SI1868579T1 (sl) 2011-02-28
PT1868579E (pt) 2010-12-03
DOP2006000057A (es) 2006-09-30
CR9348A (es) 2008-02-13
AU2006222365A1 (en) 2006-09-14
WO2006094626A1 (en) 2006-09-14
ES2351612T3 (es) 2011-02-08
AR054234A1 (es) 2007-06-13
US20080242707A1 (en) 2008-10-02
BRPI0608840A2 (pt) 2010-02-02
NO343834B1 (no) 2019-06-17
HK1118019A1 (zh) 2009-01-30
DK1868579T3 (da) 2011-01-10
CN101132779A (zh) 2008-02-27
TWI324928B (en) 2010-05-21
CN101132779B (zh) 2016-03-16
GT200600096A (es) 2007-01-12
CA2601955A1 (en) 2006-09-14
AU2006222365B2 (en) 2011-07-14
PE20061345A1 (es) 2007-01-28
US9737488B2 (en) 2017-08-22
HRP20100674T1 (hr) 2011-01-31
JP2008531741A (ja) 2008-08-14
BRPI0608840B1 (pt) 2020-04-14
HK1209620A1 (en) 2016-04-08
CU23821A3 (es) 2012-06-21
TNSN07341A1 (en) 2008-12-31
SG160364A1 (en) 2010-04-29
HN2006009702A (es) 2010-06-08
KR101335932B1 (ko) 2013-12-04
UY29410A1 (es) 2006-10-31
TW200700093A (en) 2007-01-01
CA2601955C (en) 2012-07-10
DE602006017188D1 (de) 2010-11-11
US20180036249A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
BRPI0608840B8 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
BRPI0617412B8 (pt) anticorpo antiglipicano-3, agente anticâncer compreendendo o mesmo, bem como seu uso e seu processo de produção
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0508769A (pt) forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BR0215063A (pt) Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BR0309988A (pt) Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
BR112015029260A2 (pt) derivados de tilosina e seu método de preparação

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AG (DE)

Free format text: TRANSFERIDO POR INCORPORACAO DE: BAYER HEALTHCARE AG.

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF